ATE294504T1 - Verfahren und zusammensetzungen zur behandlung von zellproliferationsstörungen - Google Patents

Verfahren und zusammensetzungen zur behandlung von zellproliferationsstörungen

Info

Publication number
ATE294504T1
ATE294504T1 AT99968523T AT99968523T ATE294504T1 AT E294504 T1 ATE294504 T1 AT E294504T1 AT 99968523 T AT99968523 T AT 99968523T AT 99968523 T AT99968523 T AT 99968523T AT E294504 T1 ATE294504 T1 AT E294504T1
Authority
AT
Austria
Prior art keywords
compositions
methods
cell proliferation
beta
inhibiting
Prior art date
Application number
AT99968523T
Other languages
English (en)
Inventor
John N Vournakis
Sergio Finkielsztein
Ernest R Pariser
Original Assignee
Marinepolymer Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marinepolymer Tech Inc filed Critical Marinepolymer Tech Inc
Application granted granted Critical
Publication of ATE294504T1 publication Critical patent/ATE294504T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/042—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/70—Polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Biotechnology (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
AT99968523T 1998-12-22 1999-12-21 Verfahren und zusammensetzungen zur behandlung von zellproliferationsstörungen ATE294504T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/218,288 US6063911A (en) 1993-12-01 1998-12-22 Methods and compositions for treatment of cell proliferative disorders
PCT/US1999/030575 WO2000036918A1 (en) 1998-12-22 1999-12-21 Methods and compositions for treatment of cell proliferative disorders

Publications (1)

Publication Number Publication Date
ATE294504T1 true ATE294504T1 (de) 2005-05-15

Family

ID=22814511

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99968523T ATE294504T1 (de) 1998-12-22 1999-12-21 Verfahren und zusammensetzungen zur behandlung von zellproliferationsstörungen

Country Status (14)

Country Link
US (1) US6063911A (de)
EP (1) EP1139752B1 (de)
JP (1) JP4795539B2 (de)
CN (1) CN100488512C (de)
AT (1) ATE294504T1 (de)
AU (1) AU780248B2 (de)
CA (1) CA2356087C (de)
DE (1) DE69925156T2 (de)
ES (1) ES2242448T3 (de)
HK (1) HK1043507B (de)
IL (2) IL143700A0 (de)
NO (1) NO330033B1 (de)
NZ (1) NZ512586A (de)
WO (1) WO2000036918A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962490A (en) 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US6541498B2 (en) 1993-05-20 2003-04-01 Texas Biotechnology Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6342610B2 (en) 1993-05-20 2002-01-29 Texas Biotechnology Corp. N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US6613804B2 (en) 1993-05-20 2003-09-02 Encysive Pharmaceuticals, Inc. Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US6376523B1 (en) 1994-05-20 2002-04-23 Texas Biotechnology Corporation Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6743783B1 (en) * 1993-12-01 2004-06-01 Marine Polymer Technologies, Inc. Pharmaceutical compositions comprising poly-β-1→4-N-acetylglucosamine
US5858350A (en) 1993-12-01 1999-01-12 Marine Polymer Technologies Methods and compositions for poly-β-1→4-N-acetylglucosamine cell therapy system
US5977117A (en) 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
US5804585A (en) 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
US6432994B1 (en) 1997-04-28 2002-08-13 Texas Biotechnology Corporation Sulfonamides for treatment of endothelin-mediated disorders
US5783705A (en) 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
US6545048B1 (en) 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
CA2385528C (en) 1999-10-01 2013-12-10 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
EP1244657B1 (de) 1999-12-31 2004-12-29 Encysive Pharmaceuticals Inc. Sulfonamide und ihre derivate, die die aktivität des endothelins modulieren
US20050245451A1 (en) * 2000-04-05 2005-11-03 Pincus Matthew R Peptides selectively lethal to malignant and transformed mammalian cells
TWI306760B (en) * 2000-08-07 2009-03-01 Abbott Lab Use of an endothelin et-a receptor antagonist and orally delivered pharmaceutical composition comprising the same
EE200300075A (et) * 2000-08-22 2004-12-15 Boehringer Ingelheim Pharma Kg Angiotensiin II antagonistide ja ACE inhibiitorite farmatseutiline kombinatsioon
US7041657B2 (en) 2001-02-12 2006-05-09 Marine Polymer Technologies Inc. Compositions and methods for modulation of vascular structure and/or function
DE10155076A1 (de) * 2001-11-09 2003-05-22 Merck Patent Gmbh Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
GB0223854D0 (en) * 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
WO2004060172A1 (en) * 2002-12-31 2004-07-22 Marine Polymer Technologies, Inc. Hemostatic compositions and uses therefor
KR20050098249A (ko) * 2003-01-17 2005-10-11 쓰레솔드 파마슈티컬스, 인코포레이티드 양성 전립선 비대증의 치료방법
EP1601757B1 (de) 2003-02-24 2016-11-30 Marine Polymer Technologies, Inc. Zellen-polymerfaser-zusammensetzungen und deren verwendung
WO2004100991A1 (en) * 2003-05-15 2004-11-25 Universite Catholique De Louvain Use of endothelin-1 antagonists for improving cancer therapy
US8152750B2 (en) * 2003-09-12 2012-04-10 Marine Polymer Technologies, Inc. Vascular access preservation in hemodialysis patients
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
EP1734821A4 (de) * 2004-04-14 2011-07-06 Uab Research Foundation Aktivatoren der hexosaminbiosynthese als hemmer für durch ischämieschock oder hämorrhagischen schock induzierte schäden
PL1899364T5 (pl) 2005-05-17 2024-12-09 University Of Connecticut Kompozycje i sposoby immunomodulacji w organizmie
EP1984505B1 (de) 2006-01-13 2019-12-25 The Government of the U.S.A., as repr. by the Secretary, Dept. of Health & Human Services, the Nat. Inst. of Health Codonoptimierte il-15- und il-15r-alpha-gene zur expression in säugerzellen
ES2552842T3 (es) 2007-02-19 2015-12-02 Marine Polymer Technologies, Inc. Composiciones hemostáticas y regímenes terapéuticos
CA2691785C (en) * 2007-06-27 2017-01-10 Marine Polymer Technologies Inc. Complexes of il-15 and il-15ralpha and uses thereof
WO2009070650A1 (en) * 2007-11-26 2009-06-04 The Research Foundation Of State University Of New York Small molecule cancer treatments that cause necrosis in cancer cells but do not affect normal cells
EP3135294B1 (de) 2009-08-14 2020-06-03 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Verwendung von il-15 zur erhöhung der thymusleistung und zur behandlung von lymphopenie
AU2011239466B2 (en) 2010-04-15 2015-01-22 Marine Polymer Technologies, Inc. Anti-bacterial applications of poly -N-acetylglucosamine nanofibers
MX356877B (es) 2011-04-15 2018-06-19 Marine Polymer Tech Inc Tratamiento de enfermedades con nanofibras de poli-n-acetil-glucosamina.
GB201616087D0 (en) * 2016-09-21 2016-11-02 Tomalgae Cvba Algae comprising therapeutic and/or nutritional agents
WO2019195851A1 (en) 2018-04-06 2019-10-10 Oncolyze, Inc. Compositions for use in lysis of selective cancer cells

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1038367A (en) * 1963-05-28 1966-08-10 Beecham Group Ltd Penicillin derivatives
US3989535A (en) * 1974-02-11 1976-11-02 American Cyanamid Company Solution of poly(N-acetyl-D-glucosamine)
US3988411A (en) * 1974-02-11 1976-10-26 American Cyanamid Company Spinning and shaping poly-(N-acetyl-D-glucosamine)
JPS55152705A (en) * 1979-05-18 1980-11-28 Mitsubishi Rayon Co Ltd Preparation of water-soluble alkali chitin
US4378017A (en) * 1980-03-21 1983-03-29 Kureha Kagaku Kogyo Kabushiki Kaisha Composite material of de-N-acetylated chitin and fibrous collagen
JPS5927826A (ja) * 1982-08-10 1984-02-14 Masuko Suzuki 抗感染症剤
US4803168A (en) * 1983-09-01 1989-02-07 Damon Biotech, Inc. Microencapsulation with polymers
US4749620A (en) * 1984-02-15 1988-06-07 Massachusetts Institute Of Technology Encapsulated active material system
IL80032A (en) * 1985-09-23 1992-07-15 Lilly Co Eli Anti-tumor phenyl-aminocarbonylsulfonamides,their preparation and pharmaceutical compositions containing them
JPS62288602A (ja) * 1986-06-06 1987-12-15 Agency Of Ind Science & Technol キトサン変性物粒子の製造方法
US4942129A (en) * 1987-07-28 1990-07-17 Queen's University At Kingston Multiple membrane microencapsulation
US5571821A (en) * 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
US5008116A (en) * 1988-11-14 1991-04-16 Frederick Cahn Immunostimulatory microsphere
US5071977A (en) * 1989-05-10 1991-12-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Plaque inhibiting oligosaccharide
US5116747A (en) * 1989-08-11 1992-05-26 University Of Waterloo Immobilization of biologically active material in capsules prepared from a water-soluble polymer and chitosan acetate
US5529914A (en) * 1990-10-15 1996-06-25 The Board Of Regents The Univeristy Of Texas System Gels for encapsulation of biological materials
JPH04334322A (ja) * 1991-05-09 1992-11-20 Unitika Ltd 抗腫瘍剤
US5382569A (en) * 1991-05-16 1995-01-17 Warner-Lambert Company Endotherlin antagonists
CA2072395A1 (en) * 1991-07-01 1993-01-02 John T. Hunt Bicyclic endothelin analogues
US5219749A (en) * 1991-10-09 1993-06-15 Institute For Molecular Biology & Biotechnology/Forth Process for isolating and preparing purified chitin deacetylase
US5229123A (en) * 1991-10-09 1993-07-20 Hoffmann-La Roche Inc. Antifungal agents
CA2121129A1 (en) * 1991-10-29 1993-05-13 Patrick Soon-Shiong Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release
PL176250B1 (pl) * 1991-11-05 1999-05-31 Smithkline Beecham Corp Sposób wytwarzania pochodnych indanu
IL100096A (en) * 1991-11-20 1996-03-31 Univ Ramot Method for entrapment of active materials in chitosan
US5260002A (en) * 1991-12-23 1993-11-09 Vanderbilt University Method and apparatus for producing uniform polymeric spheres
US5573934A (en) * 1992-04-20 1996-11-12 Board Of Regents, The University Of Texas System Gels for encapsulation of biological materials
US5550110A (en) * 1992-04-22 1996-08-27 Warner-Lambert Company Endothelin Antagonists II
WO1994003483A1 (en) * 1992-07-30 1994-02-17 Chiron Corporation Endothelin receptor-binding compounds
TW394761B (en) * 1993-06-28 2000-06-21 Hoffmann La Roche Novel Sulfonylamino Pyrimidines
US5858350A (en) * 1993-12-01 1999-01-12 Marine Polymer Technologies Methods and compositions for poly-β-1→4-N-acetylglucosamine cell therapy system
US5624679A (en) * 1993-12-01 1997-04-29 Marine Polymer Technologies, Inc. Methods and compositions for poly-β-1-4-N-acetylglucosamine biological barriers
US5622834A (en) * 1993-12-01 1997-04-22 Marine Polymer Technologies, Inc. Method of isolating poly-β-1-4-N-acetylglucosamine from microalgal culture
WO1996011927A1 (en) * 1994-10-12 1996-04-25 Abbott Laboratories Endothelin antagonists
TW313568B (de) * 1994-12-20 1997-08-21 Hoffmann La Roche
US5658943A (en) * 1995-01-05 1997-08-19 Warner-Lambert Company Phenylalanine derivatives as endothelin antagonists
AU5917896A (en) * 1995-06-06 1996-12-24 Marine Polymer Technologies, Inc. Poly-beta-1-4-N-acetylglucosamine
AU6603996A (en) * 1995-08-24 1997-03-19 Warner-Lambert Company Furanone endothelin antagonists
WO1997037987A1 (en) * 1996-04-10 1997-10-16 Warner-Lambert Company Ketoacid endothelin antagonists

Also Published As

Publication number Publication date
WO2000036918A1 (en) 2000-06-29
JP2003522732A (ja) 2003-07-29
DE69925156T2 (de) 2006-02-16
AU2591900A (en) 2000-07-12
US6063911A (en) 2000-05-16
CA2356087A1 (en) 2000-06-29
CA2356087C (en) 2009-02-17
NO20013071L (no) 2001-08-20
CN1335749A (zh) 2002-02-13
NO20013071D0 (no) 2001-06-20
JP4795539B2 (ja) 2011-10-19
IL143700A (en) 2006-08-01
NO330033B1 (no) 2011-02-07
HK1043507A1 (zh) 2002-09-20
EP1139752B1 (de) 2005-05-04
AU780248B2 (en) 2005-03-10
ES2242448T3 (es) 2005-11-01
CN100488512C (zh) 2009-05-20
NZ512586A (en) 2004-01-30
DE69925156D1 (de) 2005-06-09
EP1139752A4 (de) 2003-01-02
WO2000036918A9 (en) 2000-11-23
HK1043507B (zh) 2009-12-24
EP1139752A1 (de) 2001-10-10
IL143700A0 (en) 2002-04-21

Similar Documents

Publication Publication Date Title
EP1139752A4 (de) Verfahren und zusammensetzungen zur behandlung von zellproliferationsstörungen
DE60327786D1 (de) Kdr-peptide und diese enthaltende impfstoffe
DE69631141D1 (de) Biologisch aktive peptide und ihre zubereitungen und verwendungen
BR0211200A (pt) Peptìdeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células
GB9924957D0 (en) Novel treatment
ATE217889T1 (de) Humane antikörper gegen faktor ix/ixa
ID25509A (id) Anti pembekuan protein
DE60143818D1 (de) Alpha-fetoprotein-peptide und ihre verwendung
FR2861731B1 (fr) Nouvelle proteine de fixation du phosphate, compositions pharmaceutiques la contenant et ses utilisations
GB0010314D0 (en) Anti-freeze proteins their production and use
DE59410132D1 (de) Humanes zirkulierendes cytokin cc-1
LV10108A (lv) Sunu proliferacijas inhibitori farmaceitiska kompozicija savienojumu iegusanas metode sunu proliferacijas inhibesanas panemieni
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
ATE250427T1 (de) Zusammensetzungen und deren verwendung zur hemmung von angiogenese
ATE263239T1 (de) Produkte des keratinocyten-wachstumsfaktors 2 (kgf-2)
WO2007013358A3 (en) Vivit polypeptides, therapeutic agent comprising the same, and method of screening for anti-cancer agent
EE200000510A (et) CD137 kasutamine perifeersete monotsüütide vohamise soodustamiseks
ATE325812T1 (de) Menschliches, gebärmutterkrebs-spezifisches suppressorprotein, für das protein kodieres polynukleotid, mit dem polynukleotid transformierte zelle und verfahren zur unterdrückung der proliferation von krebszellen unter verwendung des expressionsvektors
AU2118500A (en) Transcription factor e2f dna-binding domain inhibitor peptides and their use

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties